Bangkok Genomics Innovation PCL (BKK:BKGI) Debt-to-EBITDA : 0.26 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bangkok Genomics Innovation PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ฿4.5 Mil. Bangkok Genomics Innovation PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ฿16.0 Mil. Bangkok Genomics Innovation PCL's annualized EBITDA for the quarter that ended in Sep. 2024 was ฿78.6 Mil. Bangkok Genomics Innovation PCL's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Debt-to-EBITDA or its related term are showing as below:

BKK:BKGI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 0.41 Max: 0.61
Current: 0.33

During the past 5 years, the highest Debt-to-EBITDA Ratio of Bangkok Genomics Innovation PCL was 0.61. The lowest was 0.09. And the median was 0.41.

BKK:BKGI's Debt-to-EBITDA is ranked better than
81.31% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs BKK:BKGI: 0.33

Bangkok Genomics Innovation PCL Debt-to-EBITDA Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Debt-to-EBITDA Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

N/A

0.61

0.09

0.34

0.48

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-EBITDA	Get a 7-Day Free Trial						-	0.54	0.40	0.30	0.26

Competitive Comparison of Bangkok Genomics Innovation PCL's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Debt-to-EBITDA falls into.

Bangkok Genomics Innovation PCL Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bangkok Genomics Innovation PCL's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.285	+	19.435)	/	49.547
	=	0.48

Bangkok Genomics Innovation PCL's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.487	+	16.044)	/	78.56
	=	0.26

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.

Bangkok Genomics Innovation PCL (BKK:BKGI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Bangkok Genomics Innovation PCL Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Scientific testing services which generates key revenue, and Sale of goods.